Your browser doesn't support javascript.
Pregnancy and infant outcomes by trimester of SARS-CoV-2 infection in pregnancy-SET-NET, 22 jurisdictions, January 25, 2020-December 31, 2020.
Neelam, Varsha; Reeves, Emily L; Woodworth, Kate R; O'Malley Olsen, Emily; Reynolds, Megan R; Rende, Joy; Wingate, Heather; Manning, Susan E; Romitti, Paul; Ojo, Kristen D; Silcox, Kristin; Barton, Jerusha; Mobley, Evan; Longcore, Nicole D; Sokale, Ayomide; Lush, Mamie; Delgado-Lopez, Camille; Diedhiou, Abdoulaye; Mbotha, Deborah; Simon, Wanda; Reynolds, Bethany; Hamdan, Tahani S; Beauregard, Suzann; Ellis, Esther M; Seo, Jennifer Y; Bennett, Amanda; Ellington, Sascha; Hall, Aron J; Azziz-Baumgartner, Eduardo; Tong, Van T; Gilboa, Suzanne M.
  • Neelam V; Centers for Disease Control and Prevention COVID-19 Response, Epidemiology Task Force, Atlanta, Georgia, USA.
  • Reeves EL; Centers for Disease Control and Prevention COVID-19 Response, Epidemiology Task Force, Atlanta, Georgia, USA.
  • Woodworth KR; Eagle Global Scientific, LLC, Atlanta, Georgia, USA.
  • O'Malley Olsen E; Centers for Disease Control and Prevention COVID-19 Response, Epidemiology Task Force, Atlanta, Georgia, USA.
  • Reynolds MR; Centers for Disease Control and Prevention COVID-19 Response, Epidemiology Task Force, Atlanta, Georgia, USA.
  • Rende J; Centers for Disease Control and Prevention COVID-19 Response, Epidemiology Task Force, Atlanta, Georgia, USA.
  • Wingate H; New Jersey Department of Health, Trenton, New Jersey, USA.
  • Manning SE; Tennessee Department of Health, Nashville, Tennessee, USA.
  • Romitti P; Centers for Disease Control and Prevention COVID-19 Response, Epidemiology Task Force, Atlanta, Georgia, USA.
  • Ojo KD; Massachusetts Department of Public Health, Boston, Massachusetts, USA.
  • Silcox K; University of Iowa College of Public Health, Iowa City, Iowa, USA.
  • Barton J; Minnesota Department of Health, St. Paul, Minnesota, USA.
  • Mobley E; Maryland Department of Health, Baltimore, Maryland, USA.
  • Longcore ND; Georgia Department of Public Health, Atlanta, Georgia, USA.
  • Sokale A; Missouri Department of Health and Senior Services, Jefferson City, Missouri, USA.
  • Lush M; New York State Department of Health, Albany, New York, USA.
  • Delgado-Lopez C; Philadelphia Department of Public Health, Philadelphia, Pennsylvania, USA.
  • Diedhiou A; Nebraska Department of Health and Human Services, Lincoln, Nebraska, USA.
  • Mbotha D; Puerto Rico Department of Health, San Juan, Puerto Rico, USA.
  • Simon W; South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
  • Reynolds B; Washington State Department of Health, Shoreline, Washington, USA.
  • Hamdan TS; Arkansas Department of Health, Little Rock, Arkansas, USA.
  • Beauregard S; Pennsylvania Department of Health, Pittsburgh, Pennsylvania, USA.
  • Ellis EM; Houston Health Department, Houston, Texas, USA.
  • Seo JY; New Hampshire Department of Health and Human Services, Concord, New Hampshire, USA.
  • Bennett A; U.S. Virgin Islands Department of Health, Christiansted, Virgin Islands, USA.
  • Ellington S; Chicago Department of Public Health, Chicago, Illinois, USA.
  • Hall AJ; Centers for Disease Control and Prevention COVID-19 Response, Epidemiology Task Force, Atlanta, Georgia, USA.
  • Azziz-Baumgartner E; Illinois Department of Public Health, Chicago, Illinois, USA.
  • Tong VT; Centers for Disease Control and Prevention COVID-19 Response, Epidemiology Task Force, Atlanta, Georgia, USA.
  • Gilboa SM; Centers for Disease Control and Prevention COVID-19 Response, Epidemiology Task Force, Atlanta, Georgia, USA.
Birth Defects Res ; 2022 Sep 06.
Article in English | MEDLINE | ID: covidwho-2233725
ABSTRACT

OBJECTIVES:

We describe clinical characteristics, pregnancy, and infant outcomes in pregnant people with laboratory-confirmed SARS-CoV-2 infection by trimester of infection. STUDY

DESIGN:

We analyzed data from the Surveillance for Emerging Threats to Mothers and Babies Network and included people with infection in 2020, with known timing of infection and pregnancy outcome. Outcomes are described by trimester of infection. Pregnancy outcomes included live birth and pregnancy loss (<20 weeks and ≥20 weeks gestation). Infant outcomes included preterm birth (<37 weeks gestation), small for gestational age, birth defects, and neonatal intensive care unit admission. Adjusted prevalence ratios (aPR) were calculated for pregnancy and selected infant outcomes by trimester of infection, controlling for demographics.

RESULTS:

Of 35,200 people included in this analysis, 50.8% of pregnant people had infection in the third trimester, 30.8% in the second, and 18.3% in the first. Third trimester infection was associated with a higher frequency of preterm birth compared to first or second trimester infection combined (17.8% vs. 11.8%; aPR 1.44 95% CI 1.35-1.54). Prevalence of birth defects was 553.4/10,000 live births, with no difference by trimester of infection.

CONCLUSIONS:

There were no signals for increased birth defects among infants in this population relative to national baseline estimates, regardless of timing of infection. However, the prevalence of preterm birth in people with SARS-CoV-2 infection in pregnancy in our analysis was higher relative to national baseline data (10.0-10.2%), particularly among people with third trimester infection. Consequences of COVID-19 during pregnancy support recommended COVID-19 prevention strategies, including vaccination.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study / Prognostic study Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Bdr2.2081

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study / Prognostic study Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Bdr2.2081